- See Also
-
Links
- “The Association between Glucose-Dependent Insulinotropic Polypeptide And/or Glucagon-Like Peptide-1 Receptor Agonist Prescriptions and Substance-Related Outcomes in Patients With Opioid and Alcohol Use Disorders: A Real-World Data Analysis”, Qeadan et al 2024
- “The Association between Glucose-Dependent Insulinotropic Polypeptide And/or Glucagon-Like Peptide-1 Receptor Agonist Prescriptions and Substance-Related Outcomes in Patients With Opioid and Alcohol Use Disorders: A Real-World Data Analysis”, Qeadan et al 2024
- “Why Do Obesity Drugs Seem to Treat so Many Other Ailments?”
- “[The Hunger-Noise Monster]”
- “NYC Law Student Addicted to Cheese Went to Nearly $6K-Per-Week Rehab”, Levine & Sedacca 2024
- “They Promoted Body Positivity. Then They Lost Weight: Do Plus-Size Influencers Owe Their Followers an Explanation When Their Bodies Change?”, Baker 2024
- “Substantial Decrease in Alcohol Use Disorder Symptoms Secondary to Semaglutide Therapy for Weight Loss: A Case Series”, Richards et al 2023
- “Sharon Osbourne Quit Ozempic Because She’s ‘Too Skinny’”, Wickman 2023
- “GWAS of Random Glucose in 476,326 Individuals Provide Insights into Diabetes Pathophysiology, Complications and Treatment Stratification”, Lagou et al 2023
- “People on Drugs Like Ozempic Say Their ‘Food Noise’ Has Disappeared: For Some, It’s a Startling Side Effect”, Blum 2023
- “Brain Responses to Nutrients Are Severely Impaired and Not Reversed by Weight Loss in Humans With Obesity: a Randomized Crossover Study”, Galen et al 2023
- “What the Scientists Who Pioneered Weight-Loss Drugs Want You to Know”, Reynolds 2023
- “I Lost 40 Pounds on Ozempic. But I’m Left With Even More Questions.”, Marcus 2023
- “Ozempic’s Next Act: People Taking the Drug for Weight Loss Say They Have Also Stopped Drinking, Smoking, Shopping, and Even Nail-Biting”, Zhang 2023
- “Effects of Liraglutide on Depressive Behavior in a Mouse Depression Model and Cognition in the Probe Trial of Morris Water Maze Test”, Seo et al 2023b
- “Feasibility of Exenatide, a GLP-1R Agonist, for Treating Cocaine Use Disorder: A Case Series Study”, Yammine et al 2023
- “Semaglutide Reduces Alcohol Intake and Relapse-Like Drinking in Male and Female Rats”, Aranäs et al 2023
- “The Potential Antidepressant Effect of Antidiabetic Agents: New Insights from a Pharmacovigilance Study Based on Data from the Reporting System Databases FAERS and VigiBase”, Battini et al 2023
- “Protective Role of IGF-1 and GLP-1 Signaling Activation in Neurological Dysfunctions”, Bhalla et al 2022
- “Dose Titration With the Glucagon-Like Peptide-1 Agonist, Liraglutide, Reduces Cue- and Drug-Induced Heroin Seeking in High Drug-Taking Rats”, Evans et al 2022
- “Glucagon-Like Peptide 1 Receptor Activation Inhibits Microglial Pyroptosis via Promoting Mitophagy to Alleviate Depression-Like Behaviors in Diabetic Mice”, Yang et al 2022
- “Treating Cognitive Impairment in Schizophrenia With GLP-1RAs: an Overview of Their Therapeutic Potential”, Flintoff et al 2021
- “Testing the Effects of the GLP-1 Receptor Agonist Exenatide on Cocaine Self-Administration and Subjective Responses in Humans With Cocaine Use Disorder”, Angarita et al 2021
- “Activation of GLP-1 Receptors Attenuates Oxycodone Taking and Seeking without Compromising the Antinociceptive Effects of Oxycodone in Rats”, Zhang et al 2020
- “GABA Neurons in the Nucleus Tractus Solitarius Express GLP-1 Receptors and Mediate Anorectic Effects of Liraglutide in Rats”, Fortin et al 2020
- “Glucagon-Like Peptide-1 Receptors within the Nucleus of the Solitary Tract Regulate Alcohol-Mediated Behaviors in Rodents”, Vallöf et al 2019
- “Effects of Glucagon-Like Peptide 1 Analogs on Alcohol Intake in Alcohol-Preferring Vervet Monkeys”, Thomsen et al 2019
- “Longer-Term Liraglutide Administration at the Highest Dose Approved for Obesity Increases Reward-Related Orbitofrontal Cortex Activation in Response to Food Cues: Implications for Plateauing Weight Loss in Response to Anti-Obesity Therapies”, Farr et al 2019
- “Glucagon-Like Peptide-1 Receptor Agonists for Antipsychotic-Associated Cardio-Metabolic Risk Factors: A Systematic Review and Individual Participant Data Meta-Analysis”, Siskind et al 2018
- “Liraglutide for Psychiatric Disorders: Clinical Evidence and Challenges”, Camkurt et al 2018
- “Cognitive Dysfunction and Metabolic Comorbidities in Mood Disorders: A Repurposing Opportunity for Glucagon-Like Peptide 1 Receptor Agonists?”, Mansur et al 2018
- “Glucagon-Like Peptide-1 Receptor Activation in the Ventral Tegmental Area Attenuates Cocaine Seeking in Rats”, Hernandez et al 2018
- “No Cognitive-Enhancing Effect of GLP-1 Receptor Agonism in Antipsychotic-Treated, Obese Patients With Schizophrenia”, Ishøy et al 2017
- “Central & Peripheral Glucagon-Like Peptide-1 Receptor Signaling Differentially Regulate Addictive Behaviors”, Sirohi et al 2016
- “Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Prevents Development of Tolerance to Anti-Anxiety Effect of Ethanol and Withdrawal-Induced Anxiety in Rats”, Sharma et al 2014
- “Neuronal GLP1R Mediates Liraglutide’s Anorectic but Not Glucose-Lowering Effect”, Sisley et al 2014
- “Liraglutide: Short-Lived Effect on Gastric Emptying—Long Lasting Effects on Body Weight”, Jelsing et al 2012
- “Drugs Developed to Treat Diabetes, Liraglutide and Lixisenatide, Cross the Blood Brain Barrier and Enhance Neurogenesis”, Hunter & Hölscher 2012
- “Peripheral and Central GLP-1 Receptor Populations Mediate the Anorectic Effects of Peripherally Administered GLP-1 Receptor Agonists, Liraglutide and Exendin-4”, Kanoski et al 2011
- Sort By Magic
- Wikipedia
- Miscellaneous
- Bibliography
See Also
Links
“The Association between Glucose-Dependent Insulinotropic Polypeptide And/or Glucagon-Like Peptide-1 Receptor Agonist Prescriptions and Substance-Related Outcomes in Patients With Opioid and Alcohol Use Disorders: A Real-World Data Analysis”, Qeadan et al 2024
“The Association between Glucose-Dependent Insulinotropic Polypeptide And/or Glucagon-Like Peptide-1 Receptor Agonist Prescriptions and Substance-Related Outcomes in Patients With Opioid and Alcohol Use Disorders: A Real-World Data Analysis”, Qeadan et al 2024
“Why Do Obesity Drugs Seem to Treat so Many Other Ailments?”
“[The Hunger-Noise Monster]”
“NYC Law Student Addicted to Cheese Went to Nearly $6K-Per-Week Rehab”, Levine & Sedacca 2024
NYC law student addicted to cheese went to nearly $6K-per-week rehab
“They Promoted Body Positivity. Then They Lost Weight: Do Plus-Size Influencers Owe Their Followers an Explanation When Their Bodies Change?”, Baker 2024
“Substantial Decrease in Alcohol Use Disorder Symptoms Secondary to Semaglutide Therapy for Weight Loss: A Case Series”, Richards et al 2023
“Sharon Osbourne Quit Ozempic Because She’s ‘Too Skinny’”, Wickman 2023
“GWAS of Random Glucose in 476,326 Individuals Provide Insights into Diabetes Pathophysiology, Complications and Treatment Stratification”, Lagou et al 2023
“People on Drugs Like Ozempic Say Their ‘Food Noise’ Has Disappeared: For Some, It’s a Startling Side Effect”, Blum 2023
“Brain Responses to Nutrients Are Severely Impaired and Not Reversed by Weight Loss in Humans With Obesity: a Randomized Crossover Study”, Galen et al 2023
“What the Scientists Who Pioneered Weight-Loss Drugs Want You to Know”, Reynolds 2023
What the Scientists Who Pioneered Weight-Loss Drugs Want You to Know
“I Lost 40 Pounds on Ozempic. But I’m Left With Even More Questions.”, Marcus 2023
I lost 40 pounds on Ozempic. But I’m left with even more questions.
“Ozempic’s Next Act: People Taking the Drug for Weight Loss Say They Have Also Stopped Drinking, Smoking, Shopping, and Even Nail-Biting”, Zhang 2023
“Effects of Liraglutide on Depressive Behavior in a Mouse Depression Model and Cognition in the Probe Trial of Morris Water Maze Test”, Seo et al 2023b
“Feasibility of Exenatide, a GLP-1R Agonist, for Treating Cocaine Use Disorder: A Case Series Study”, Yammine et al 2023
Feasibility of Exenatide, a GLP-1R Agonist, for Treating Cocaine Use Disorder: A Case Series Study
“Semaglutide Reduces Alcohol Intake and Relapse-Like Drinking in Male and Female Rats”, Aranäs et al 2023
Semaglutide reduces alcohol intake and relapse-like drinking in male and female rats
“The Potential Antidepressant Effect of Antidiabetic Agents: New Insights from a Pharmacovigilance Study Based on Data from the Reporting System Databases FAERS and VigiBase”, Battini et al 2023
“Protective Role of IGF-1 and GLP-1 Signaling Activation in Neurological Dysfunctions”, Bhalla et al 2022
Protective role of IGF-1 and GLP-1 signaling activation in neurological dysfunctions
“Dose Titration With the Glucagon-Like Peptide-1 Agonist, Liraglutide, Reduces Cue- and Drug-Induced Heroin Seeking in High Drug-Taking Rats”, Evans et al 2022
“Glucagon-Like Peptide 1 Receptor Activation Inhibits Microglial Pyroptosis via Promoting Mitophagy to Alleviate Depression-Like Behaviors in Diabetic Mice”, Yang et al 2022
“Treating Cognitive Impairment in Schizophrenia With GLP-1RAs: an Overview of Their Therapeutic Potential”, Flintoff et al 2021
“Testing the Effects of the GLP-1 Receptor Agonist Exenatide on Cocaine Self-Administration and Subjective Responses in Humans With Cocaine Use Disorder”, Angarita et al 2021
“Activation of GLP-1 Receptors Attenuates Oxycodone Taking and Seeking without Compromising the Antinociceptive Effects of Oxycodone in Rats”, Zhang et al 2020
“GABA Neurons in the Nucleus Tractus Solitarius Express GLP-1 Receptors and Mediate Anorectic Effects of Liraglutide in Rats”, Fortin et al 2020
“Glucagon-Like Peptide-1 Receptors within the Nucleus of the Solitary Tract Regulate Alcohol-Mediated Behaviors in Rodents”, Vallöf et al 2019
“Effects of Glucagon-Like Peptide 1 Analogs on Alcohol Intake in Alcohol-Preferring Vervet Monkeys”, Thomsen et al 2019
Effects of glucagon-like peptide 1 analogs on alcohol intake in alcohol-preferring vervet monkeys
“Longer-Term Liraglutide Administration at the Highest Dose Approved for Obesity Increases Reward-Related Orbitofrontal Cortex Activation in Response to Food Cues: Implications for Plateauing Weight Loss in Response to Anti-Obesity Therapies”, Farr et al 2019
“Glucagon-Like Peptide-1 Receptor Agonists for Antipsychotic-Associated Cardio-Metabolic Risk Factors: A Systematic Review and Individual Participant Data Meta-Analysis”, Siskind et al 2018
“Liraglutide for Psychiatric Disorders: Clinical Evidence and Challenges”, Camkurt et al 2018
Liraglutide for psychiatric disorders: clinical evidence and challenges
“Cognitive Dysfunction and Metabolic Comorbidities in Mood Disorders: A Repurposing Opportunity for Glucagon-Like Peptide 1 Receptor Agonists?”, Mansur et al 2018
“Glucagon-Like Peptide-1 Receptor Activation in the Ventral Tegmental Area Attenuates Cocaine Seeking in Rats”, Hernandez et al 2018
“No Cognitive-Enhancing Effect of GLP-1 Receptor Agonism in Antipsychotic-Treated, Obese Patients With Schizophrenia”, Ishøy et al 2017
“Central & Peripheral Glucagon-Like Peptide-1 Receptor Signaling Differentially Regulate Addictive Behaviors”, Sirohi et al 2016
“Neuronal GLP1R Mediates Liraglutide’s Anorectic but Not Glucose-Lowering Effect”, Sisley et al 2014
Neuronal GLP1R mediates liraglutide’s anorectic but not glucose-lowering effect
“Liraglutide: Short-Lived Effect on Gastric Emptying—Long Lasting Effects on Body Weight”, Jelsing et al 2012
Liraglutide: short-lived effect on gastric emptying—long lasting effects on body weight
“Drugs Developed to Treat Diabetes, Liraglutide and Lixisenatide, Cross the Blood Brain Barrier and Enhance Neurogenesis”, Hunter & Hölscher 2012
“Peripheral and Central GLP-1 Receptor Populations Mediate the Anorectic Effects of Peripherally Administered GLP-1 Receptor Agonists, Liraglutide and Exendin-4”, Kanoski et al 2011
Sort By Magic
Annotations sorted by machine learning into inferred 'tags'. This provides an alternative way to browse: instead of by date order, one can browse in topic order. The 'sorted' list has been automatically clustered into multiple sections & auto-labeled for easier browsing.
Beginning with the newest annotation, it uses the embedding of each annotation to attempt to create a list of nearest-neighbor annotations, creating a progression of topics. For more details, see the link.
body-image
glp1-research
addiction-regulation
liraglutide-impact
Wikipedia
Miscellaneous
Bibliography
-
https://www.nytimes.com/2024/02/26/style/body-positive-influencers-weight-loss.html: “They Promoted Body Positivity. Then They Lost Weight: Do Plus-Size Influencers Owe Their Followers an Explanation When Their Bodies Change?”, -
2023-richards.pdf: “Substantial Decrease in Alcohol Use Disorder Symptoms Secondary to Semaglutide Therapy for Weight Loss: A Case Series”, -
2023-vangalen.pdf: “Brain Responses to Nutrients Are Severely Impaired and Not Reversed by Weight Loss in Humans With Obesity: a Randomized Crossover Study”, -
https://www.wired.com/story/obesity-drugs-researcher-interview-ozempic-wegovy/: “What the Scientists Who Pioneered Weight-Loss Drugs Want You to Know”, -
https://www.theatlantic.com/health/archive/2023/05/ozempic-addictive-behavior-drinking-smoking/674098/: “Ozempic’s Next Act: People Taking the Drug for Weight Loss Say They Have Also Stopped Drinking, Smoking, Shopping, and Even Nail-Biting”, -
https://www.sciencedirect.com/science/article/pii/S0028390819300541: “Glucagon-Like Peptide-1 Receptors within the Nucleus of the Solitary Tract Regulate Alcohol-Mediated Behaviors in Rodents”,